FDA Brief

Warning letters Drugs

FDA warning letter to

Wittman Pharma, Inc.

High riskIssued Aug 6, 2024Posted Sep 24, 2024Division of Pharmaceutical Quality Operations II

FDA warns Wittman Pharma, an OTC drug maker in Brooksville, Florida, that weak quality oversight and contaminated water make its products adulterated.

What happened

FDA inspected Wittman Pharma's Brooksville, Florida drug manufacturing facility from February 6 to March 15, 2024, and reviewed the company's March 20, 2024 response. Investigators found the quality unit released a batch of OTC drug product before finished-product microbial testing was done, that senior management downgraded a deviation so no investigation was required for discolored tablets, and that the company's water system was not properly qualified and repeatedly grew objectionable microorganisms, including Burkholderia cepacia, while product made with that water was released. FDA also found the company did not test each lot of propylene glycol for identity, including the test that detects diethylene glycol and ethylene glycol.

What FDA found

  1. The quality unit let a batch ship before finished-product testing, including microbial testing, was complete, which also broke the company's own procedures.

    21 CFR 211.22
  2. Senior management overrode the quality unit and changed a discoloration deviation from moderate to minor, so no investigation was done and no root cause was found.

    21 CFR 211.192
  3. The water system used to make drugs was never properly qualified: it showed objectionable microorganisms including Burkholderia cepacia and other out-of-specification results, and product made with that water was still released.

    21 CFR 211.100(a)
  4. Each lot of propylene glycol was not tested for identity, including the USP limit test for diethylene glycol and ethylene glycol, which are toxic.

    21 CFR 211.84(d)(1)
  5. Finished product testing was not adequate to show each batch was free of objectionable microorganisms.

    21 CFR 211.165(b)
  6. Written procedures for cleaning and maintaining equipment were not adequate or not followed.

    21 CFR 211.67(b)

What FDA wants

FDA tells the company to correct the violations promptly and reply in writing within 15 working days with what it has done and how it will prevent recurrence. FDA also asks the company to clarify whether it intends to keep making drugs at this or any other facility and to hire a qualified CGMP consultant to do a full six-system audit.

Who should pay attention

  • brands and retailers selling store-brand OTC cough, cold and allergy medicines made at this plant
  • companies that buy finished OTC drug products from this contract manufacturer
  • drugmakers that rely on water system qualification and component identity testing at their own sites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

    FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

    High risk
  4. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk